New York: Researchers have developed a new use for a common blood test, which could provide potentially life-saving treatment for heart failure.
The symptoms of low cardiac T3 are also virtually indistinguishable from other conditions that lead to heart failure, suggesting that a significant number of underlying heart dysfunction and heart failure symptoms may actually be caused by a treatable T3 hormone imbalance.
“Despite this treatability, clinicians are hesitant to prescribe T3 to heart patients, as too much of the hormone could accidentally trigger an irregular heartbeat,” the study authors from New York Institute of Technology (NYIT) in the US, wrote.
In addition, no method has yet been identified to titrate, or continually measure and adjust, for the dosage of T3 needed to safely restore the heart’s thyroid hormone function.
Now, an existing biomarker called brain natriuretic peptide (BNP) may provide the much-needed solution, the researchers said.
In medicine, biomarkers are biological molecules found in a patient’s blood, fluid, or tissue sample that can indicate whether a disease or condition is present.
They can also be used to see how well the body responds to treatments.
During heart failure, the heart will secrete higher levels of the biomarker BNP into blood, a key indication that the heart disease is worsening.
The researchers hypothesised that by analysing a patient’s BNP levels in response to added T3, clinicians could titrate for just the right dosage required.